GACAT2: A Potential Drug Target and Biomarker (G100287082)

Target Name: GACAT2

NCBI ID: G100287082

GACAT2

Other Name(s): MTCL1-AS1 | Uncharacterized LOC100287082 | MTCL1AS1 | LOC100287082 | gastric cancer associated transcript 2

GACAT2: A Potential Drug Target and Biomarker

Guanocortisol (GACAT2) is a synthetic corticosteroid that is used for the treatment of a variety of conditions including anxiety, insomnia, and skin conditions. It works by modulating the levels of various signaling molecules in the brain, including neurotransmitters such as dopamine and cortisol. One of the unique features of GACAT2 is its ability to cross the blood-brain barrier and its long half-life, which allows for once-daily dosing.

GACAT2 has been shown to be effective in treating anxiety and insomnia in both human and animal models. In a clinical trial, patients taking GACAT2 showed significant improvements in symptoms of anxiety and insomnia compared to placebo. The drug was also shown to have long-lasting effects, with improvements in symptoms lasting for several weeks after treatment.

GACAT2's effects on the brain are mediated by its ability to modulate the levels of certain signaling molecules. One of the primary targets of GACAT2 is the neurotransmitter dopamine, which is involved in mood regulation and motivation. By increasing the levels of dopamine in the brain, GACAT2 can improve mood and reduce symptoms of anxiety and insomnia.

In addition to its effects on dopamine, GACAT2 has also been shown to modulate the levels of other signaling molecules that are involved in mood and anxiety regulation, such as cortisol and neurotensin. These molecules play a critical role in regulating the body's response to stress and can contribute to the development of anxiety and insomnia. By modulating their levels, GACAT2 can have a more targeted and effective effect on mood and anxiety symptoms.

GACAT2's ability to cross the blood-brain barrier is another unique feature that makes it an attractive drug target. The blood-brain barrier is a specialized barrier that separates the brain from the blood and is designed to protect the brain from harmful substances. However, this barrier can also prevent the delivery of drugs to the brain, making it difficult to treat certain conditions. By crossing the blood-brain barrier, GACAT2 can bypass this barrier and deliver its therapeutic effects directly to the brain.

GACAT2 has also been shown to have long-lasting effects, which is an important factor in the treatment of anxiety and insomnia. Unlike many other drugs, which can have short half-lives and may need to be dosed multiple times a day, GACAT2 can be dosed once daily. This allows for patients to maintain a consistent level of the drug in their system, which is critical for long-lasting effects.

In conclusion, GACAT2 is a promising drug target and biomarker for the treatment of anxiety and insomnia. Its ability to modulate the levels of dopamine and other signaling molecules involved in mood and anxiety regulation makes it an attractive target for drug development. Furthermore, its ability to cross the blood-brain barrier and its long half-life make it an attractive option for once-daily dosing. Further research is needed to fully understand the potential of GACAT2 as a drug and to develop safe and effective treatments for anxiety and insomnia.

Protein Name: Gastric Cancer Associated Transcript 2

The "GACAT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GACAT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets